| # | Title | Journal | Year | Citations |
|---|
| 1 | A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer | New England Journal of Medicine | 2003 | 2,640 |
| 2 | Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes | Science | 2002 | 2,598 |
| 3 | Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes | Science | 2006 | 2,352 |
| 4 | Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 | Molecular Therapy | 2010 | 2,079 |
| 5 | A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes | Science | 1986 | 1,617 |
| 6 | Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma | Proceedings of the National Academy of Sciences of the United States of America | 2003 | 1,482 |
| 7 | Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired | Blood | 2009 | 1,481 |
| 8 | Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Nature Genetics | 1997 | 1,461 |
| 9 | Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer | Science | 2014 | 1,460 |
| 10 | Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1 | Journal of Clinical Oncology | 2011 | 1,427 |
| 11 | Adoptive immunotherapy for cancer: harnessing the T cell response | Nature Reviews Immunology | 2012 | 1,412 |
| 12 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Nature Reviews Cancer | 2008 | 1,404 |
| 13 | von Hippel-Lindau disease | Lancet, The | 2003 | 1,322 |
| 14 | Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens | Journal of Clinical Oncology | 2008 | 1,210 |
| 15 | Stabilization of beta -Catenin by Genetic Defects in Melanoma Cell Lines | Science | 1997 | 1,181 |
| 16 | T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer | New England Journal of Medicine | 2016 | 1,033 |
| 17 | Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance | Advances in Immunology | 1999 | 998 |
| 18 | Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4 | Journal of Clinical Oncology | 2005 | 989 |
| 19 | Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. | Proceedings of the National Academy of Sciences of the United States of America | 1994 | 987 |
| 20 | Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma | Journal of Immunotherapy | 2010 | 950 |
| 21 | Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. | Proceedings of the National Academy of Sciences of the United States of America | 1994 | 860 |
| 22 | T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis | Molecular Therapy | 2011 | 857 |
| 23 | Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. | Journal of Experimental Medicine | 1994 | 771 |
| 24 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients | Nature Medicine | 2016 | 721 |
| 25 | Impaired immunologic reactivity and recurrence following cancer surgery | Cancer | 1970 | 680 |
| 26 | High-fidelity mRNA amplification for gene profiling | Nature Biotechnology | 2000 | 650 |
| 27 | Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans | Cell Metabolism | 2014 | 643 |
| 28 | Immunogenicity of somatic mutations in human gastrointestinal cancers | Science | 2015 | 639 |
| 29 | Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer | Nature Medicine | 2018 | 637 |
| 30 | Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function | Journal of Experimental Medicine | 2005 | 636 |
| 31 | Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients | Journal of Immunotherapy | 2003 | 598 |
| 32 | Identification of human cancers deficient in antigen processing. | Journal of Experimental Medicine | 1993 | 588 |
| 33 | IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients | Blood | 2006 | 564 |
| 34 | A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens | Immunity | 1999 | 551 |
| 35 | Adoptive cell therapy for the treatment of patients with metastatic melanoma | Current Opinion in Immunology | 2009 | 539 |
| 36 | A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. | Journal of Experimental Medicine | 1996 | 532 |
| 37 | Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma | Journal of Clinical Oncology | 2002 | 512 |
| 38 | The grading of soft tissue sarcomas results of a clinicohistopathologic correlation in a series of 163 cases | Cancer | 1984 | 508 |
| 39 | Loss of Functional Beta2-Microglobulin in Metastatic Melanomas From Five Patients Receiving Immunotherapy | Journal of the National Cancer Institute | 1996 | 490 |
| 40 | Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study | Annals of Surgical Oncology | 2005 | 477 |
| 41 | Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma | Journal of Clinical Oncology | 2002 | 473 |
| 42 | Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2 | Annals of Surgery | 1998 | 451 |
| 43 | Determinants of metastatic rate and survival in patients with zollinger-ellison syndrome: A prospective long-term study | Gastroenterology | 1995 | 443 |
| 44 | Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors | Gastroenterology | 2012 | 443 |
| 45 | Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy | Journal of Immunology | 2004 | 442 |
| 46 | gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand | Journal of Experimental Medicine | 1998 | 437 |
| 47 | Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma | Journal of Immunology | 2005 | 428 |
| 48 | IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells | Journal of Immunotherapy | 2006 | 397 |
| 49 | Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer | Science | 2011 | 397 |
| 50 | IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy | Blood | 2008 | 380 |
